NASDAQ:GUTS Fractyl Health (GUTS) Stock Price, News & Analysis → Gold Mania (From Stansberry Research) (Ad) Free GUTS Stock Alerts $6.51 0.00 (0.00%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$6.50▼$6.6950-Day Range$6.25▼$10.1452-Week Range$5.75▼$14.50Volume85,334 shsAverage Volume338,020 shsMarket Capitalization$311.70 millionP/E RatioN/ADividend YieldN/APrice Target$22.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsSocial Media Get Fractyl Health alerts: Email Address Fractyl Health MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside237.9% Upside$22.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.15Based on 13 Articles This WeekInsider TradingAcquiring Shares$5 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.88) to ($2.02) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.39 out of 5 starsMedical Sector4207th out of 5,430 stocksSurgical & Medical Instruments Industry469th out of 570 stocks 3.5 Analyst's Opinion Consensus RatingFractyl Health has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageFractyl Health has only been the subject of 3 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for GUTS. Previous Next 0.0 Dividend Strength Dividend YieldFractyl Health does not currently pay a dividend.Dividend GrowthFractyl Health does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GUTS. Previous Next 2.3 News and Social Media Coverage News SentimentFractyl Health has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Fractyl Health this week, compared to 5 articles on an average week.Search InterestOnly 5 people have searched for GUTS on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.MarketBeat Follows5 people have added Fractyl Health to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Fractyl Health insiders have bought more of their company's stock than they have sold. Specifically, they have bought $4,999,995.00 in company stock and sold $0.00 in company stock. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Fractyl Health are expected to decrease in the coming year, from ($1.88) to ($2.02) per share. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-up before it’s too late. It’s urgent because it’s what we consider “The #1 Crypto for the AI World.”Learn more about it by watching THIS NOW. About Fractyl Health Stock (NASDAQ:GUTS)Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.Read More GUTS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GUTS Stock News HeadlinesMay 3, 2024 | finance.yahoo.comFractyl Health, Inc.'s (NASDAQ:GUTS) largest shareholders are private equity firms with 52% ownership, individual investors own 30%May 3, 2024 | yahoo.com22 Gut-Healthy Salads That Are High in ProteinMay 4, 2024 | Porter & Company (Ad)Elon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.May 2, 2024 | yahoo.comHack Your Health: The Secrets of Your Gut on Netflix: Meet the ParticipantsMay 1, 2024 | yahoo.com4 Supplements You Shouldn't Take for Gut Health, According to DietitiansApril 30, 2024 | cnet.comBest Probiotic Supplements for Gut HealthApril 30, 2024 | yahoo.com16 Gut-Healthy Snacks That Are High in ProteinApril 30, 2024 | msn.comWhip Your Gut Into Shape: Try These 12 Probiotic Foods to Boost Your Digestive HealthMay 4, 2024 | Porter & Company (Ad)Elon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.April 30, 2024 | globenewswire.comFractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual MeetingApril 30, 2024 | msn.comResearch uncovers Blautia bacteria's crucial role in gut health and disease protectionApril 28, 2024 | msn.com8 Gut Health Delights: Natural Probiotic Foods You'll LoveApril 28, 2024 | msn.comGut Health Benefits of Semolina: A Nutrition Professional's PerspectiveApril 28, 2024 | yahoo.comHack Your Health: The Secrets of Your Gut Streaming: Watch & Stream via NetflixApril 26, 2024 | yahoo.comBoost Gut Health and Debloat for Good With These Bestselling Greens and Wellness ShotsApril 26, 2024 | forbes.comArtificial Sweetener Could Seriously Damage Gut According To New StudyApril 21, 2024 | nytimes.com5 Gut Facts Experts Want You to KnowApril 20, 2024 | msn.comAn expert explains why you should pay more attention to your gut healthApril 18, 2024 | msn.comGive Your Gut Health a Glow-up With These 8 Expert-Approved TipsApril 17, 2024 | investorplace.comThe 3 Most Volatile Stocks for Short-Term Traders: April 2024April 13, 2024 | yahoo.com20 Easy Gut-Healthy Dinners That Are High in ProteinApril 9, 2024 | uk.investing.comFractyl Health Inc (GUTS)April 8, 2024 | msn.com10 Warning Signs Your Gut Health Is OffApril 8, 2024 | msn.comGut-friendly psychobiotics could brighten moods and fight depressionApril 4, 2024 | bizjournals.comPetri Dish: Vertex kidney drug moves into Ph 3; Fractyl preps for commercializationApril 2, 2024 | markets.businessinsider.comStrong Growth Potential and Strategic Clinical Advances Reinforce Buy Rating for Fractyl Health, Inc.April 2, 2024 | globenewswire.comFractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 DiabetesSee More Headlines Receive GUTS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fractyl Health and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/01/2024Today5/04/2024Next Earnings (Estimated)7/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:GUTS Previous SymbolNASDAQ:GUTS CUSIPN/A CIK1572616 Webfractyl.com Phone781-902-8800FaxN/AEmployees102Year FoundedN/APrice Target and Rating Average Stock Price Target$22.00 High Stock Price Target$26.00 Low Stock Price Target$18.00 Potential Upside/Downside+237.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio3.19 Quick Ratio3.18 Sales & Book Value Annual Sales$120,000.00 Price / Sales2,597.49 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares47,880,000Free FloatN/AMarket Cap$311.70 million OptionableN/A BetaN/A 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Harith Rajagopalan M.D. (Age 47)Ph.D., Co-Founder, CEO & Director Comp: $863.77kMr. Jay D. Caplan BSEE (Age 62)MBA, Co-Founder, Chief Product Officer & President Comp: $555.19kDr. Timothy J. Kieffer Ph.D. (Age 57)Chief Scientific Officer Comp: $140.64kMs. Lisa A. Davidson MBA (Age 57)CFO & Treasurer Ms. Sarah S. Toomey Esq. (Age 49)General Counsel & Corporate Secretary Comp: $479.36kDr. Helmut GiersiefenHead of Business DevelopmentMr. Adrian KimberChief Commercial OfficerMore ExecutivesKey CompetitorsBioventusNYSE:BVSCerusNASDAQ:CERSLyra TherapeuticsNASDAQ:LYRAInovio PharmaceuticalsNASDAQ:INOTactile Systems TechnologyNASDAQ:TCMDView All CompetitorsInsidersAjay RoyanBought 333,333 shares on 2/6/2024Total: $5.00 M ($15.00/share)View All Insider Transactions GUTS Stock Analysis - Frequently Asked Questions Should I buy or sell Fractyl Health stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fractyl Health in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GUTS shares. View GUTS analyst ratings or view top-rated stocks. What is Fractyl Health's stock price target for 2024? 3 Wall Street analysts have issued 1-year price targets for Fractyl Health's shares. Their GUTS share price targets range from $18.00 to $26.00. On average, they expect the company's share price to reach $22.00 in the next twelve months. This suggests a possible upside of 237.9% from the stock's current price. View analysts price targets for GUTS or view top-rated stocks among Wall Street analysts. How have GUTS shares performed in 2024? Fractyl Health's stock was trading at $12.85 at the start of the year. Since then, GUTS stock has decreased by 49.3% and is now trading at $6.51. View the best growth stocks for 2024 here. When is Fractyl Health's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, July 1st 2024. View our GUTS earnings forecast. How were Fractyl Health's earnings last quarter? Fractyl Health, Inc. (NASDAQ:GUTS) released its quarterly earnings data on Monday, April, 1st. The company reported ($8.02) EPS for the quarter. The business had revenue of $0.01 million for the quarter. When did Fractyl Health IPO? Fractyl Health (GUTS) raised $110 million in an IPO on Friday, February 2nd 2024. The company issued 7,333,333 shares at a price of $15.00 per share. When does Fractyl Health's lock-up period expire? Fractyl Health's lock-up period expires on Wednesday, July 31st. Fractyl Health had issued 7,333,333 shares in its initial public offering on February 2nd. The total size of the offering was $109,999,995 based on an initial share price of $15.00. After the expiration of Fractyl Health's lock-up period, major shareholders and company insiders will be able to sell their shares of the company. How do I buy shares of Fractyl Health? Shares of GUTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GUTS) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchAutomatic Income (from home)Awesomely, LLCClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsCould Your Accounts Be Frozen?Allegiance GoldFW: 234x GainWeiss RatingsStock-Picking AI Predicts #1 Stock of 2024Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fractyl Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.